1 - 10 of 40 articles
There are advantages of integrated transplant centers, within the nation's academic medical centers, but there are also potential difficulties in navigating the fiscal and administrative relationships. See also article by Howard and Kaplan in this issue on page 2225.
New laboratory criteria for predicting organ performance at the time of transplantation are needed, but any proposed test requires robust multi‐centric validation before it can become widely accepted as standard of care. See also articles by Anglicheau and Philosophe in this issue on pages 2316...
Treatment of recurrent hepatitis C may prolong graft survival in carefully selected patients. See also article by Veldt et al in this issue on page 2426.
Kidney transplant recipients are at higher risk of cancer at most sites, and cancer after transplantation causes considerable morbidity and mortality. To optimize long‐term patient outcomes, clinicians balance the prospect of graft failure and dialysis, with competing risks of diabetes,...
Skin cancers are the most frequent malignancies in organ transplant recipients (OTR), with 95% being nonmelanoma skin cancers (NMSC), especially squamous (SCC) and basal cell carcinomas. Most OTR with a first SCC subsequently develop multiple NMSC within 5 years, highlighting the concept of...
Globally approximately 15% of all malignant tumors are caused by viruses and even a higher percentage is observed in organ transplant recipients (OTR). Here, nonmelanoma skin cancer (NMSC) is the most frequent malignancy, which correlates with cutaneous human papilloma virus (HPV) infection. In...
The increased risk for the development of malignancies in transplant recipients is generally attributed to the debilitated immune system that results from chronic exposure to potent immunosuppressive drugs required to prevent graft rejection. While impaired immunity is clearly a key determinant,...
One of the most clinically important molecular signalling networks to emerge over the past decade is the mammalian target of rapamycin (mTOR) pathway. mTOR, the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.